A pre-clinical study [55] suggested that βKlotho mediates FGF9 pro-survival functions in hepatocellular carcinoma via FGFR3 and FGFR4 and may be useful in selecting patients who could benefit from anti-FGFR therapies. The gene discussed is FGF9; the disease is hepatocellular carcinoma.